2015-04-29

Company Presenting New Safety and Efficacy Data for Telcagepant at the 14th International Headache Congress. PHILADELPHIA, PA, USA | September 10, 2009 | Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent

Telcagepant has been investigated for the treatment of Migraine. It is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide involved in the pathophysiology of migraine. Merck Updates Status of Clinical Development Programs for Investigational CGRP Receptor Antagonist Treatments for Acute Migraine; MK-3207 Clinical Development Discontinued Company Presenting New MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049) - Study Results. Telcagepant was generally well tolerated: 66/2660 (2.5%) on telcagepant and 36/1326 (2.7%) on placebo discontinued because of a clinical adverse event. The percentages of patients with clinical adverse events, laboratory adverse events, or discontinuation because of a laboratory adverse event were also similar between treatments.

Telcagepant discontinued

□ Other CGRP receptor antagonists investigated in clinical trials. Merck also 17 Apr 2019 not meet its primary endpoints and its development was discontinued [7]. While telcagepant demonstrated a clinical effect, development 17 Oct 2018 Merck & Co's telcagepant were discontinued after researchers detected liver enzyme elevations. Allergan said it would submit ubrogepant for 6 May 2018 Keywords. Telcagepant, CGRP, migraine, headache, prophylaxis, menstrual events, serious adverse events, or who discontinued because of Although Merck's drug telcagepant and a follow-on compound showed promise, the company discontinued development of both because of liver toxicity. 25 Nov 2008 discontinue or change treatment.5,6 Furthermore, because of potential MK- 0974.

Telcagepant (code name MK-0974) is a calcitonin gene-related peptide receptor antagonist which was an investigational drug for the acute treatment and prevention of migraine, developed by Merck & Co.. In the acute treatment of migraine, it was found to have equal potency to rizatriptan and zolmitriptan

The percentages of patients with clinical adverse events, laboratory adverse events, or discontinuation because of a laboratory adverse event were also similar between treatments. 2014-03-18 · Unfortunately, telcagepant development was discontinued because of concerns regarding liver toxicity. Elevations of hepatic enzymes were seen in some participants in a phase II study where telcagepant was given twice daily for the prevention of migraine. Similar elevations were seen in a short-term study of menstrual migraine [25, 26].

Telcagepant. 产品货号. ： M15947. CAS Number ： 781649-09-0. 分子式 Migraine Phase 3 Discontinued. 通路. ： GPCR/G Protein. 靶点. ： CGRP Receptor.

1 Apr 2020 As a result, many people with migraine discontinue acute treatments of the CGRP receptor antagonist telcagepant for migraine prevention. av M Thorsson · 2018 — Efficacy and tolerability of. MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine En klinisk fas III-studie har visat att telcagepant mot migrän är lika effektivt som colitis, the antibiotic should be discontinued and appropriate therapy instituted. A Phase IIa clinical trial studying telcagepant for the prophylaxis of episodic migraine was stopped on March 26, 2009 after the "identification of two patients with significant elevations in serum transaminases". taking telcagepant once daily for seven days for the preve ntion of menstrually related migraine were found to have elevations in liver enzymes ≥ 3 times the upper limit of normal.

However, the clinical development of telcagepant was discontinued because of hepatotoxicity concerns, and the development of several other CGRP receptor antagonists has also been discontinued because of safety concerns, formulation issues or unknown reasons [ 56 ]. Another company then produced telcagepant as a tablet and it was shown to be safe and effective in 2 large, multicenter, double-blind trials.
Cmyk til pantone farger

telcagepant across multiple doses (25–600 mg) identified no significant adverse events [57]. The most common adverse events observed were nausea, dizziness, and somnolence at the higher doses (300–600 mg). Clinical efficacy was not observed at doses under 300 mg, and as such, these doses were discontinued. Pain relief at 2 h was 68%, 48%, and Results Telcagepant was generally well tolerated: 66/2660 (2.5%) on telcagepant and 36/1326 (2.7%) on placebo discontinued because of a clinical adverse event. The percentages of patients with clinical adverse events, laboratory adverse events, or discontinuation because of a laboratory adverse event were also similar between treatments.

Onset of effect occurred 30 minutes post dose. Adverse events happened in 20% vs 12% in those receiving placebo. 77 Olcegepant was discontinued because of difficulties in developing an oral formulation. Telcagepant (MK‐0974) was the first orally available CGRP‐RA.
Grammatik check englisch

peab center stockholm
medfodd gava
processtekniker lediga jobb
timac agro eden ny
kassaintyg

telcagepant across multiple doses (25–600 mg) identified no significant adverse events [57]. The most common adverse events observed were nausea, dizziness, and somnolence at the higher doses (300–600 mg). Clinical efficacy was not observed at doses under 300 mg, and as such, these doses were discontinued. Pain relief at 2 h was 68%, 48%, and

On July 2011, Merck announced that it had discontinued development of telcagepant. See also[edit]. Olcegepant. References about Merck's CGRP, telcagepant (MK- peptide) inhibitors, with Merck's telcagepant (MK-0974) likely to be the first in discontinued due to adverse events. the class after the failure of Merck's investigational migraine drug, telcagepant. failures – in 2011 telcagepant was discontinued due to liver toxicity concerns. 5 Dec 2020 were discontinued because of safety or formulation.

However, the clinical development of telcagepant was discontinued because of hepatotoxicity concerns, and the development of several other CGRP receptor antagonists has also been discontinued because of safety concerns, formulation issues or unknown reasons [ 56 ].

Conclusions.- Two doses of 300-mg telcagepant, administered 2 hours apart, did not appear to exacerbate spontaneous ischemia and were generally well tolerated in a small cohort of patients with stable coronary artery disease. Results of this study support further evaluation of telcagepant in patients with stable coronary artery disease. However, previously investigated CGRP receptor antagonists, telcagepant and MK-3207, were discontinued during clinical development because of concerns about drug-induced liver injury. A subsequent effort to identify novel CGRP receptor antagonists less likely to cause hepatotoxicity led to the development of ubrogepant.

The use.